PMID- 31093103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Print)
IS  - 1020-4989 (Linking)
VI  - 42
DP  - 2018
TI  - Yellow fever vaccine and risk of developing serious adverse events: a systematic 
      review.
PG  - e75
LID - 10.26633/RPSP.2018.75 [doi]
LID - e75
AB  - OBJECTIVE: To evaluate contraindications and precautions for the yellow fever 
      vaccine (YFV) in risk populations. METHODS: A literature review was conducted by 
      searching PubMed for "yellow fever vaccine" and "adverse events" (AEs); 207 
      studies were found, and 43 of them met the inclusion criteria and were included 
      in a systematic review. RESULTS: The results for first dose of YFV in elderly 
      patients were conflicting-some showed AEs while some showed benefits. Therefore, 
      precaution and case-by-case decisionmaking for YFV in this population are 
      advised. The same precautions are warranted for YFV in infants 6-8 months, with 
      the vaccine contraindicated in those < 6 months old and safe after 9 months of 
      age. YFV seems safe in the first trimester of pregnancy, and probably throughout 
      gestation, as it was not associated with increased malformations. During 
      breastfeeding, YFV continues to be controversial. The vaccine seems safe in 
      people being treated with immunomodulatory or immunosuppressive therapy, people 
      with immunosuppressive diseases, and solid organ and hematopoietic stem cell 
      transplant patients; in stem cell transplants, however, a booster dose should 
      only be applied once immunity is recovered. HlV-infected patients with a CD4+ 
      count > 200 cells/mm(3) do not have increased risk of AEs from YFV. Egg allergy 
      vaccination protocols seem to provide a safe way to immunize these patients. 
      CONCLUSIONS: YFV safety has been confirmed based on data from many vaccination 
      campaigns and multiple studies. AEs seem more frequent after a first-time dose, 
      mainly in risk groups, but this review evaluated YFV in several of the same risk 
      groups and the vaccine was found to be safe in most of them.
FAU - Porudominsky, Ruben
AU  - Porudominsky R
AD  - Universidad Peruana Cayetano Heredia, Lima, Peru.
FAU - Gotuzzo, Eduardo H
AU  - Gotuzzo EH
AD  - Universidad Peruana Cayetano Heredia, Lima, Peru.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180605
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC6386100
OTO - NOTNLM
OT  - Yellow fever
OT  - drug-related side effects and adverse reactions
OT  - risk groups
OT  - systematic review
OT  - yellow fever vaccine
COIS- Conflicts of interest. None.
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:01
PMCR- 2018/06/05
CRDT- 2019/05/17 06:00
PHST- 2017/05/16 00:00 [received]
PHST- 2017/08/11 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:01 [medline]
PHST- 2018/06/05 00:00 [pmc-release]
AID - RPSP.2018.75 [pii]
AID - 10.26633/RPSP.2018.75 [doi]
PST - epublish
SO  - Rev Panam Salud Publica. 2018 Jun 5;42:e75. doi: 10.26633/RPSP.2018.75. 
      eCollection 2018.